Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:26 14/05/2026 am IST			5-day change	1st Jan Change
113.45 ^USD	+0.96%		-0.10%	+7.78%

13/05	European shares lifted by miners and tech; Mideast in focus	RE
12/05	Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at Asco 2026	RE

Press Releases

12/05	Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026	BU
08/05	Merck : Statement on Daiichi Sankyo Update to Manufacturing and Supply Plan - Merck.com	PU
07/05	Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate	BU
05/05	Merck Completes Acquisition of Terns Pharmaceuticals, Inc.	BU
30/04	Merck : Icon 1Q26 Merck Earnings Announcement	PU
30/04	Merck : Icon 1Q26 Merck Earnings Presentation	PU
30/04	Merck: Q1 Earnings Snapshot	AQ
30/04	Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones	BU
28/04	Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke	BU
27/04	Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.	AQ
24/04	Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.	BU
22/04	Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation	PR
21/04	FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)	BU
21/04	Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)	BU
20/04	FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer	BU
17/04	European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season	BU
15/04	New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada	AQ
13/04	Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy	BU
13/04	Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy	BU
07/04	Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.	BU
02/04	Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration	BU
02/04	European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens	BU
01/04	Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30	BU
30/03	Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins	BU
30/03	Merck - Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR in Adults with the Syndrome of Combined Post and Precapillary Pulmonary Hypertension and Heart Failure	AQ